
Thousands arrested in France protests + Ozempic: The good, the bad, the ugly
Monday Headlines:
- Jordon Steele-John releases lengthy statement, says he’s not on leave
- Violent cost of living protests sweep France with more than 2000 arrested
- Trump endorses Netanyahu as his administration calls for more to be done over Israeli settler violence in the West Bank
- Pope Leo makes first public appearance since lung surgery
- Katie Zachariah fired after five days in White House press secretary role
Deep Dive: They started out treating type 2 diabetes. Now hundreds of thousands of Australians are taking them, many for a completely different reason.
GLP-1s. You probably know them as Ozempic, Wegovy and Mounjaro.
And the more people sign up, the longer the fine print gets. There are side effects GPs are still learning about, prices many can’t afford, and growing concern about online clinics posting pens to people they’ve never met.
So, years after they went from diabetes medication to weight-loss wonder drug... what do we actually know about them?
In this episode of The Briefing, Chris Spyrou is joined by Dr Michael Wright, President of the Royal Australian College of GPs, to unpack what we’ve learnt about these drugs, who should be taking them, and who definitely shouldn’t.
Follow The Briefing:
TikTok: @thebriefingpod
Instagram: @thebriefingpodcast
YouTube: @TheBriefingPodcast
See omnystudio.com/listener for privacy information.
Otros episodios de "The Briefing"



No te pierdas ningún episodio de “The Briefing”. Síguelo en la aplicación gratuita de GetPodcast.








